This is a study to evaluate the safety and efficacy of tildacerfont in pediatric subjects with Congenital Adrenal Hyperplasia (CAH). Treatment will consist of 12 weeks of continuous dosing followed by safety follow up.
An investigation of the safety and efficacy of tildacerfont in pediatric subjects with CAH.